INTRODUCTION
Studies over the last decade have shown that assessment of central blood pressure (CBP) provides important insights into the assessment of cardiovascular (CV) risk [1] .
Conduit Artery Function Evaluation (CAFE) was a sub-study [2] of the Anglo-Scandinavian
Cardiac
Outcomes Trial-Blood Pressure
Lowering Arm (ASCOT-BPLA) study [3] , which compared a combination of newer antihypertensive treatments with a combination of standard drugs. The ASCOT-BPLA study showed that calcium channel blockade with amlodipine (AML) combined with renin-angiotensin system (RAS) blockade using the angiotensin-converting enzyme inhibitor (ACEI), perindopril (PER), produced significant benefits in terms of preventing major CV events and being associated with a lower incidence of new-onset diabetes compared with the b-blocker atenolol plus the diuretic bendroflumethiazide [3] . The CAFE sub-study was significant as it showed that patients treated with the calcium channel blocker (CCB) plus ACEI combination showed significantly larger reductions in central systolic blood pressure (CSBP) despite each group showing comparable levels of blood pressure (BP) measured by the conventional seated method. This indicated that the outcome benefits of the CCB plus ACEI combination seen in ASCOT-BPLA may have resulted from differences in CBP [2] .
Observations such as these have led to increasing interest in CBP as a marker of CV risk, and its potential value is acknowledged by the 2013 European Society of Hypertension/ European Society of Cardiology (ESH/ESC) hypertension guidelines [4] .
Since the publication of the CAFE study, the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) has shown that compared with ACEI treatment, RAS blockade with an angiotensin II receptor blocker (ARB) provides equivalent CV protection combined with better tolerability [5] . However, information about the effects of an ARB plus CCB combination on CBP relative to an ACEI plus CCB combination is lacking.
Olmesartan medoxomil (OLM) is an ARB associated with strong antihypertensive efficacy, including 24-h BP reduction, and good tolerability [6] [7] [8] . Combination therapy with OLM and AML has been shown to provide increased BP-lowering capabilities compared with either agent as monotherapy [9, 10] .
Furthermore, the fixed-dose combination containing these two agents (Sevikar 
METHODS
The rationale and design of this randomized, double-blind, non-inferiority study (Clinicaltrials.gov Identifier: NCT01101009) have been described before [11] . Briefly, the study comprised a 2-to 4-week open-label run-in (which included a wash out from former antihypertensive treatment and ended with all patients receiving AML 10 mg) and a 24-week, double-blind treatment period. The study was carried out at 16 Safety parameters included adverse events (classified according to intensity as mild, moderate or severe), vital signs (heart rate and standing BP), and physical examinations. Laboratory tests were performed at study inclusion and additionally at the investigator's discretion.
Statistical Analysis
The primary objective was to show noninferiority (one-sided, a = 0.025) of OLM/AML 40/10 mg compared with PER/AML 8/10 mg for the change in CSBP from Week 0 to the FE, which was analyzed by parametric analysis of covariance (ANCOVA) with treatment as a main effect and baseline CSBP as a covariate using the LOCF approach. Due to the study design (non-inferiority), the main conclusions of the statistical analyses of the primary efficacy endpoint were based on the per protocol set (PPS), which included all members of the full analysis set (FAS) with no major protocol deviations. The FAS included all randomized patients who took at least one dose of double-blind medication and had CSBP measured at baseline and on at least one occasion during double-blind treatment.
The FAS was used to analyze all efficacy variables, and was considered confirmatory for all except the primary efficacy variable due to the nature of the study (noninferiority). The safety analysis set contained all enrolled patients who took at least one dose of AML during the run-in. The number and percentage of patients with normalized BP at Week 24 were analyzed with a v 2 test using the LOCF approach.
Treatment with OLM/AML was to be considered non-inferior compared with PER/ AML if the upper limit of the two-sided 95% confidence interval (CI) for the difference in least-squares means for the change from baseline in CSBP between the two groups was less than 2 mmHg. If the upper limit of the 95% CI was less than 0 mmHg, then OLM/AML was to be considered superior to PER/AML. In a protocol amendment effected by a slowdown in recruitment, the power calculation was changed to 80% and the sample size of the PPS to 194 patients per treatment group.
RESULTS

Patients
The first patient entered the study in April Table 1 . There were no significant differences in patient characteristics between the two treatment groups and demographic characteristics were also similar in the FAS and PPS groups. For the overall study population, mean age was 60.9 years, mean weight was 86.7 kg and mean body mass • Did not provide efficacy measurement (n = 23)
• Major protocol deviation (n = 23)
• Did not receive allocated intervention (n = 1)
• Did not provide efficacy measurement (n = 20)
• Major protocol deviation (n = 29) Fig. 1 Patient flow. AE adverse events, AML amlodipine, BP blood pressure, FAS full analysis set, OLM olmesartan, PER perindopril, PPS per protocol set, SAF safety analysis set possessed by patients was four (37.3%), followed by three (29.7%) and five (22.3%).
Treatment Patterns
Overall, the mean duration of treatment was 152.6 days, and there were no major differences between the two treatment groups, including the duration of add-on HCTZ treatment. The mean (±standard deviation) dose of HCTZ was 10.6 (±9.61) mg in the OLM/AML group and 14.2 (±8.88) mg in the PER/AML group. Overall adherence was 99.3% in the OLM/AML group and 99.2% in the PER/AML group.
Primary Efficacy Variable
The absolute reduction in CSBP from baseline to the FE was statistically significantly larger in patients randomized to OLM/AML than PER/ AML (Fig. 2) . The point estimate for the betweengroup difference was -4.2 (SE 1.18) mmHg (95% CI -6.48 to -1.83 mmHg) in the PPS (Fig. 3) . The upper limit of the CI was within the 2 mmHg non-inferiority margin and so OLM/AML 40/10 mg was established as non-inferior to PER/AML 8/10 mg (p\0.0001). Furthermore, superiority of OLM/AML over PER/AML was indicated because the 95% CI for the treatment (Fig. 3) .
Secondary Efficacy Variables
As with the primary efficacy parameter, the superiority of OLM/AML over PER/AML was established for the majority of the secondary variables. 
Hemodynamic variables
Augmentation Index
In the OLM/AML group, a reduction in augmentation index was seen from baseline to FE of -1.3% (SE 0.65%). In contrast, a slight increase of 0.3% (SE 0.65%) was seen in the PER/ AML group. The point estimate (95% CI) for the difference between OLM/AML and PER/AML was -1.67% (-3.48, 0.14).
Safety/Tolerability
Each treatment was well tolerated, and the proportion of patients with one or more drugrelated treatment-emergent adverse events (TEAEs) was comparable for the OLM/AML (25.0%) and PER/AML (25.7%) groups. In the OLM/AML group, 5.7% of patients discontinued due to a drug-related TEAE and 7.5% did so in the PER/AML group ( Table 2 ). The most common adverse event was peripheral edema, which was reported in 17.8% of OLM/AML patients and 18.1% of PER/AML recipients. Nasopharyngitis was reported in 4.5% of Data are number of patients (%) AML amlodipine, OLM olmesartan, PER perindopril, TEAE treatment-emergent adverse event OLM/AML patients and 5.8% of PER/AML patients, and cough was reported in 2.0% of OLM/AML patients and 6.6% of PER/AML patients ( Table 2) .
DISCUSSION
The Growing evidence that CBP may predict CV damage and events more accurately than seated BP measurements has led to increased interest in studies using this index of CV risk [1, 4] . Following on from the CAFE study, the SEVITENSION study aimed to assess whether combined RAS and calcium channel blockade that the drug used was a significant determinant of BP reductions [6] . It was evident from these data that OLM provided consistently strong BPlowering properties over 24 h and during the last few hours of the dosing interval [6] . More recently, the widely used ACEI, ramipril, was directly compared with OLM in a population of elderly patients. The study showed that OLMbased treatment was associated with significantly larger BP reductions, including larger and more sustained reductions in BP over 24 h, a higher rate of BP goal achievement and more effective buffering of the early morning BP surge compared to ramipril [7, 15] . 
